ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
3 Results
- ACMG Practice GuidelinesOpen Archive
Screening for fetal aneuploidy and neural tube defects
Genetics in MedicineVol. 11Issue 11p818–821Published in issue: November, 2009- Deborah A. Driscoll
- Susan J. Gross
- for the Professional Practice Guidelines Committee
Cited in Scopus: 63Maternal serum screening for neural tube defects and fetal aneuploidy in the second trimester has been incorporated into obstetrical practice over the past two decades. Now, as a result of several multicenter trials, first trimester screening between 11 and 14 weeks has been shown to be an effective and reliable screening test for Down syndrome and trisomy 18. This policy updates the American College of Medical Genetics policy statement entitled Second Trimester Maternal Serum Screening for Fetal Open Neural Tube Defects and Aneuploidy (2004), incorporates First trimester diagnosis and screening for fetal aneuploidy (2008) and complements the sections of American College of Medical Genetic's Standards and Guidelines for Clinical Genetics Laboratories entitled Prenatal Screening for Down syndrome (2005) and Prenatal Screening for Open Neural Tube Defects (2005). - ACMG-Practice-GuidelinesOpen Archive
First trimester diagnosis and screening for fetal aneuploidy
Genetics in MedicineVol. 10Issue 1p73–75Published in issue: January, 2008- Deborah A. Driscoll
- Susan J. Gross
- for the Professional Practice and Guidelines Committee
Cited in Scopus: 44Maternal serum screening for neural tube defects and fetal aneuploidy in the second trimester has been incorporated into obstetrical practice over the past two decades. Now, as a result of several multicenter trials, first trimester screening between 11 and 14 weeks has been shown to be an effective and reliable screening test for Down syndrome and trisomy 18. Benefits of first trimester screening include earlier identification of the pregnancy at risk for fetal aneuploidy and anatomic defects, in particular, cardiac anomalies, and the option of earlier diagnosis by chorionic villus sampling, if available. - ACMG Practice GuidelinesOpen Archive
Second trimester maternal serum screening for fetal open neural tube defects and aneuploidy
Genetics in MedicineVol. 6Issue 6p540–541Published in issue: November, 2004- Deborah A. Driscoll
Cited in Scopus: 14Maternal serum screening has been modified during the past 25 years and is now widely utilized during the second trimester to identify women at risk for fetal open neural tube defects (ONTDs), anencephaly, and trisomies 21 and 18. This statement replaces the 1994 and 1996 ACMG position statements on serum screening and discusses clinical guidelines for screening that complement the sections of ACMG’s Standards and Guidelines for Clinical Genetics Laboratories entitled “Prenatal screening for open neural tube defects” and “Prenatal screening for Down syndrome” ( http://www.acmg.net ).
